Related Blog Posts from the Wikinvest Wire

Bristol-Myers Squibb Company (BMY)   Subscribe to Bristol-Myers Squibb Company (BMY) content from the Wikinvest Wire
 » Back to Bristol-Myers S… (NYSE:BMY) Stock Page

  

4/14/14Company Update (NYSE:BMY): Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fi... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company announced today the submission of a new drug application on April 4, 2014 to the U.S. Food and Drug Administration for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz®, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of [...]

4/7/14Market Update (NYSE:BMY): Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company announced today that they have submitted new drug applications with the U.S. Food and Drug Administration for the investigational products daclatasvir , an NS5A replication complex inhibitor, and asunaprevir , a NS3 protease inhibitor. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $83.29B, started the [...]

3/27/14Company Update (NYSE:BMY): In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. today announced the results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial that assessed the effect of blood pressure control on outcomes as well as the treatment effect of Eliquis compared to warfarin according to blood pressure control.1 The results showed that poor [...]

3/17/14Market Update (NYSE:BMY): Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agr... (Jutia Group)

[at noodls] - "This strategic alliance is evidence that our protein discovery platform is ideally suited to identify novel immune checkpoint targets for the development of next generation immuno-oncology therapeutics." ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $89.90B, opened this morning at $54.48.   Looking at [...]

3/14/14Stock Update (NYSE:BMY): U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application ( Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $89.11B, started the session at $54.15.   Looking at the stock, its [...]

3/5/14Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Presents Promisin... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today presented 24-week Phase IIb data that demonstrated similar response rates for its investigational compound, BMS-663068, when compared to a boosted protease inhibitor, Reyataz® with ritonavir. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $93.91B, started the session at $56.22.   Looking [...]

3/4/14Company Update (NYSE:BMY): Bristol-Myers Squibb’s Management Presents at Cowen Health Care Conf... (Jutia Group)

[Seeking Alpha] - Well, good morning and welcome to the Bristol-Myers Squibb session of Cowen’s 34th Annual Healthcare Conference. We are very pleased to have Bristol with us again this year. Representing the company is Dr. Brian Daniels, who is Senior Vice President, Global Development and Medical Affairs. Bristol has been and continues to [...]

2/25/14Bristol-Myers Squibb Company (NYSE:BMY) | FDA approves Bristol-Myers drug for rare body fat disorder (Jutia Group)

[Reuters] - Bristol-Myers Squibb Co said the U.S. Food and Drug Administration approved its drug to treat rare and potentially fatal disorders involving loss of body fat. The drug has been approved as a replacement therapy to treat complications caused by leptin hormone deficiency in patients with congenital or acquired generalized lipodystrophy. Generalized lipodystrophy [...]

2/24/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Receives U.S. FDA ... (Jutia Group)

[at noodls] - FDA grants Designation request for investigational daclatasvir (DCV) and asunaprevir (ASV) combination therapy for treatment of genotype 1b chronic hepatitis C (HCV) infection Marks second Breakthrough ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $90.19B, opened this morning at $54.24.   Looking at the [...]

2/21/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – In a Subanalysis, Eliquis® (apixaban) ... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. today announced results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial in relation to patient age. ARISTOTLE was designed to evaluate the efficacy and safety of Eliquis compared to warfarin for reducing the risk of stroke or systemic embolism in patients with nonvalvular [...]

2/20/14Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Present at Cowen and Company ... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will present at the Cowen and Company 34th Annual Global Health Care Conference on Tuesday, March 4, 2014, in Boston. Brian Daniels, senior vice president, Global Development and Medical Affairs, will make a formal presentation about the company at 10 a.m. Read more on this. Bristol-Myers Squibb [...]

2/14/14Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Present at Ci... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will present at the Citi 2014 Global Health Care Conference on Monday, February 24, 2014, in New York. Francis Cuss, executive vice president and chief scientific officer, will make a formal presentation about the company at 2:40 p.m. Read more on this. Bristol-Myers Squibb Company (BMY), with [...]

2/5/14Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Take Part in Leerink Swann Gl... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will take part in the Leerink Swann Global Health Care Conference on Wednesday, February 12, 2014, in New York. Charles Bancroft, executive vice president and chief financial officer, will answer questions about the company at 10:15 a.m. Read more on this. Bristol-Myers Squibb Company (BMY), currently valued [...]

1/27/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – One Factor Driving Bristol-Myers Squibb... (Jutia Group)

[at TheStreet] - Bristol-Myers Squibb (BMY) falls after concerns about the rate at which the company is developing a new combination of cancer treatment drugs. The New York City-based company announced Friday that it was ... Read more on this. Bristol-Myers Squibb Company (BMY), with a current market cap of $81.87B, opened at [...]

1/24/14Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Reports Fourth Quarter and Full ... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company’s announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. Read more on this. Bristol-Myers [...]

1/22/14Company Update (NYSE:BMY): High Stakes Intrigue In Hep C: Bristol-Myers Vs. Gilead (Jutia Group)

[at Seeking Alpha] - Gilead's ( GILD ) reluctance to marry its Hep C drug Sovaldi with Bristol-Myers Squibb's ( BMY ) daclatasvir forced Bristol to take evasive action. Bristol applied to the European Union for approval of ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $90.25B, opened at $54.74. [...]

1/16/14Bristol-Myers Squibb Company (NYSE:BMY) ~ AstraZeneca and Bristol-Myers Squibb Diabetes Alliance ... (Jutia Group)

[Business Wire] - AstraZeneca and Bristol-Myers Squibb Company today announced that the companies’ U.S. Diabetes Alliance is providing a three-year grant to the American Diabetes Association’s Pathway to Stop Diabetes program. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $89.93B, opened this morning at $54.25.   Looking at [...]

1/14/14Bristol-Myers Squibb Company (NYSE:BMY) | Bristol-Myers Ties Hepatitis C Success to Gilead’s Pill (Jutia Group)

[at Bloomberg] - Bristol-Myers Squibb Co. will try to grab an early share of the multibillion-dollar market for new hepatitis C treatments by piggybacking its experimental drug with Gilead Sciences Inc.’s approved pill.... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $91.79B, opened at $55.49.   Looking at [...]

1/10/14Bristol-Myers Squibb Company (NYSE:BMY) ~ How Will the Top Line Change for Repligen in 2014? (Jutia Group)

[at Motley Fool] - Repligen will lose an important royalty revenue stream from Bristol-Myers Squibb this year. How will that affect its top line for investors? Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $91.97B, started the session at $55.82.   During today's session, BMY [...]

1/9/14Company Update – Bristol-Myers Squibb Company (NYSE:BMY) – Forxiga Approval Should Be Boon Fo... (Jutia Group)

[at Seeking Alpha] - Both AstraZeneca PLC ( AZN ) and the Bristol-Myers Squibb Co. ( BMY ) are anticipated beneficiaries of the U.S. Food and Drug Administration announcement Wednesday that it has approved Forxiga (dapagliflozin) ... Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $90.68B, opened at [...]

1/8/14Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Daclatasvir Marketing Authorization A... (Jutia Group)

[at noodls] - Bristol-Myers Squibb application supports use of daclatasvir in combination with other agents for treating HCV patients with genotypes 1, 2, 3 and 4 Submission includes EU's first all-oral and ribavirin-free ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $87.33B, opened this morning at $52.42.   [...]

1/6/14Company Update – Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Present at... (Jutia Group)

[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will present at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2014, in San Francisco. Lamberto Andreotti, chief executive ... Read more on this. Bristol-Myers Squibb Company (BMY), with a current market cap of $86.76B, started the session at $53.07.   [...]

1/3/14Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Take Part in Goldman Sachs He... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company announced today that it will take part in Goldman Sachs Healthcare CEOs Unscripted Conference on Tuesday, January 7, 2014, in Boston. Lamberto Andreotti, chief executive officer, will answer questions about the company at 10:15 a.m. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $87.09B, began [...]

1/2/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Vs. Roche In The B... (Jutia Group)

[at Seeking Alpha] - In January, Bristol-Myers Squibb ( BMY ) , will start a Phase 2 study in patients with glioblastoma. The trial is part of a series in which Bristol combines its experimental drug, nivolumab, with the approved ... Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $87.04B, [...]

12/27/13Bristol-Myers Squibb Company (NYSE:BMY) | [$$] Bristol-Myers’ AstraZeneca Deal Is a Win (Jutia Group)

[at Barrons.com] - Hilliard Lyons Bristol-Myers Squibb agreed to sell its part of a diabetes-care collaboration to its partner, AstraZeneca. The two companies have collaborated on the development and commercialization of ... Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $87.58B, started the session at $53.66.   [...]

12/20/13Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Should Dividend Growth Investors Give U... (Jutia Group)

[at Seeking Alpha] - Bristol-Myers Squibb ( BMY ) announced its annual dividend increase on Thursday, December 19th. Here are some quick recaps from the announcement: The new quarterly dividend is 36 cents per share.This is ... Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $87.88B, began trading this morning [...]

12/19/13Bristol-Myers Squibb Company (NYSE:BMY) – Interesting BMY Put And Call Options For January 2014 (Jutia Group)

[at Forbes] - Investors in Bristol-Myers Squibb Co. (NYSE: BMY) saw new options begin trading today, for the January 2014 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BMY options chain for the new January 2014 contracts and identified one put and one call contract of particular [...] [...]

12/18/13Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – ModernGraham Valuation Of Bristol-Mye... (Jutia Group)

[at Seeking Alpha] - Here is a look at how Bristol-Myers Squibb ( BMS ) fares in ModernGraham's opinion, based on an updated and modernized version of Benjamin Graham's requirements of defensive and enterprising investors ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $84.81B, started trading this morning at $51.29. [...]

12/17/13Company Update – Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Foundation Aw... (Jutia Group)

[at noodls] - "With the conflict in Iraq now over and the conflict in Afghanistan winding down, the stakes could not be higher for service members, veterans and their families returning to garrison and civilian ... Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $83.32B, started the session [...]

12/12/13Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – FDA panel backs Bristol diabetes drug... (Jutia Group)

[Reuters] - By a lopsided vote of 13 to 1, an independent committee of medical experts on Thursday voted to recommend approval of a new type of diabetes drug from Bristol-Myers Squibb that U.S. regulators rejected two years ago due to safety concerns. The advisory panel to the U.S. Food and Drug Administration on [...]

12/10/13Bristol-Myers Squibb Company (NYSE:BMY) ~ Bristol-Myers Squibb Foundation Announces Two Grants to... (Jutia Group)

[at noodls] - "Nurses play a significant role in the delivery of care for cancer patients and in the lives of their families and caregivers and are a vital component of the health care system, disseminating patient ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $84.09B, started the session at [...]

12/9/13Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol drug for fat disorder may wor... (Jutia Group)

[Reuters] - An experimental Bristol-Myers drug to treat rare and potentially fatal disorders involving loss of body fat appears effective for some patients although with considerable safety risks, staff members of the U.S. Food and Drug Administration said on Monday. The staff observations were posted on the FDA Website ahead of a planned meeting [...]

12/6/13Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – What Everybody Ought to Know About Gi... (Jutia Group)

[at Motley Fool] - With Gilead (GILD), Johnson and Johnson (JNJ), AbbVie (ABBV), Bristol-Myers (BMY), and Merck (MRK) rushing to get next generation hepatitis C drugs to market, here are the facts you need to see. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $82.97B, began trading this morning at $51.20. [...]

12/4/13Bristol-Myers Squibb Company (NYSE:BMY) | BMY February 2014 Options Begin Trading (Jutia Group)

[at Forbes] - Investors in Bristol-Myers Squibb Co. (NYSE: BMY) saw new options begin trading today, for the February 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 80 days until expiration the newly trading contracts Read [...]

12/2/13Company Update – Bristol-Myers Squibb Company (NYSE:BMY) – Merck Faces Off Against Bristol-Me... (Jutia Group)

[at Motley Fool] - A compelling new drug in development from Merck (MRK) has a chance to change melanoma treatment, posing a threat to rapidly growing market share for Bristol Myers' (BMY) Yervoy. Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $85.34B, opened this morning at $51.29. [...]

11/22/13Company Update – Bristol-Myers Squibb Company (NYSE:BMY) – Xigduo™ (dapagliflozin and metfo... (Jutia Group)

[at noodls] - AstraZeneca and Bristol-Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $87.04B, began trading this morning at $52.34. Today’s [...]

11/14/13Bristol-Myers Squibb Company (NYSE:BMY) | Bristol-Myers Squibb Foundation Marks World Diabetes Da... (Jutia Group)

[Business Wire] - The Bristol-Myers Squibb Foundation today marked World Diabetes Day and the third anniversary of its Together on Diabetes initiative by announcing four new grants focusing on the important link between type 2 diabetes, depression and distress. Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $87.18B, [...]

11/13/13Bristol-Myers Squibb Company (NYSE:BMY) | Bristol-Myers Squibb Announces Changes in Senior Manage... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today announced a series of related changes within its Senior Management Team. To support its ongoing success as a BioPharma leader, the com Read more on this. Bristol-Myers Squibb Company (BMY), with a current market cap of $85.29B, started trading this morning at $52.09. During [...]

11/8/13Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers making R&D strategy changes (Jutia Group)

[AP] - Bristol-Myers Squibb says it is changing its research and development strategy, and will focus on some of its key drugs and experimental treatments for HIV, hepatitis B, cancer, immune conditions, and ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $85.72B, started trading this morning at $51.32. [...]

11/6/13Bristol-Myers Squibb Company (NYSE:BMY) ~ AstraZeneca Asks Court Not to Revive Whistle-Blower Suit (Jutia Group)

[at Bloomberg] - AstraZeneca Plc and Bristol-Myers Squibb Co. urged a Philadelphia federal appeals court not to revive a 10-year-old lawsuit alleging the drugmakers paid kickbacks to benefits manager Medco Health Solutions ... Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $85.69B, opened at $52.87. Looking at today's [...]

11/4/13Company Update – Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Vs. Abbvie In Potent... (Jutia Group)

[at Seeking Alpha] - Bristol-Myers Squibb ( BMY )'s new experimental drug for rheumatoid arthritis (RA) caused excitement at a conference in October. It appears that the drug clazakizumab is as effective as AbbVie ( ABBV )'s ... Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $87.31B, started trading this [...]

10/31/13Bristol-Myers Squibb Company (NYSE:BMY) – Is A Storm Brewing At Teva? (Jutia Group)

[at Seeking Alpha] - Two years ago, there was much fanfare in Israel. Teva ( TEVA ) successfully recruited Dr. Jeremy Levin, a senior executive at Bristol-Myers-Squib ( BMY ), to help jumpstart the fledgling generic drug maker. ... Read more on this. Bristol-Myers Squibb Company (BMY), with a current market cap of [...]

10/29/13Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – IncellDx Signs Agreement With Bristol-M... (Jutia Group)

[GlobeNewswire] - MENLO PARK, Calif. -- IncellDx, Inc. announced today that they have entered into an agreement with Bristol-Myers Squibb Company related to the development of an assay for potential application in a molecular ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $86.90B, started the session at $52.01. Looking at the [...]

10/28/13BMY (Samurai Trader)

BMY was one of few breakouts today, and is interesting in a couple of things I noticed here. First off, this is a cup and handle pattern, but the handle is rising rather than sloping down, which (if I recall correctly) is a pretty serious flaw. The second is the price relative line. In the right side of the base, we see lots of accumulation going on, and it continues right up the high point of the handle. At that point, the price relative line gets up to about where is was when it peaked in...

10/28/13Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Gains 6% on Promising Cancer Tre... (Jutia Group)

[at Barrons.com] - Shares of Bristol-Myers Squibb (BMY) have surged today after the pharmaceutical giant reported promising results about its lung cancer treatment over the weekend. Morgan Stanley's David Risinger and team, ... Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $85.91B, opened this morning at $50.36. Looking at [...]

10/25/13Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – 2 Big Pharma Giants Headed in Opposite ... (Jutia Group)

[at Motley Fool] - Bristol-Myers Squibb and GlaxoSmithKline both revealed their third quarter earnings recently, and what each company released shows a lot about where these firms are headed Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $80.17B, started trading this morning at $49.23. Looking at today's market, BMY one day [...]

10/24/13Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Company — Moody’s assigns A2... (Jutia Group)

[Moody's] - New York, October 24, 2013-- Moody's Investors Service assigned a rating of A2 to the new senior unsecured note offering of Bristol-Myers Squibb. There is no change to Bristol's existing ratings including ... Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $81.36B, started trading this morning at [...]

10/23/13Bristol-Myers Squibb Company (NYSE:BMY) – Ex-Bristol-Myers Executive Gets Year for Insider Trading (Jutia Group)

[at Bloomberg] - Robert Ramnarine, a former Bristol- Myers Squibb Co. executive, was sentenced to one year and a day in prison for insider trading, according to a spokeswoman for U.S. Attorney Paul Fishman. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $80.83B, began trading this morning at $49.70. Looking at today's [...]

10/22/13Bristol-Myers Squibb Company (NYSE:BMY) – Whisper Number: How Will Bristol-Myers Stock Move Aft... (Jutia Group)

[at Wall St. Cheat Sheet] - Bristol-Myers has a 42 percent positive surprise history, having topped the whisper in 11 of the 26 earnings reports for which we have data. Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $81.94B, opened this morning at $49.25. Shares have traded today between $49.21 and [...]

10/21/13Market Update on Bristol-Myers Squibb Company (NYSE:BMY) – June 2014 Options Now Available For ... (Jutia Group)

[at Forbes] - Investors in Bristol-Myers Squibb Co. (NYSE: BMY) saw new options begin trading today, for the June 2014 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 243 days until expiration the newly trading contracts represent [...] [...]


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki